

Disclosure Statement Pursuant to the Pink Basic Disclosure Guidelines

PATIENT ACCESS SOLUTIONS INC.
A NEVADA Corporation
150 VETERANS HIGHWAY
COMMACK, NY 11725

631-241-9404
WWW.PASHEALTH.COM
SIC 8090

Information Statement For the Period Ending: April 30, 2020 (the "Reporting Period")

As of April 30, 2020, the number of shares outstanding of our Common Stock was: 620,668,942
As of January 31, 2020, the number of shares outstanding of our Common Stock was: 499,435,019
As of October 31, 2019, the number of shares outstanding of our Common Stock was: 389,752,114

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Exchange Act of 1934):

Yes: o No: XX (Double-click and select "Default Value" to check)

Indicate by check mark whether the company's shell status has changed since the previous reporting period: Yes: o

No:XX

Indicate by check mark whether a Change in Control₁ of the company has occurred over this reporting period:

Yes: o No:XX

I "Change in Control" shall mean any events resulting in:

- (i) Any person (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the "beneficial owner" (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company's then outstanding voting securities;
- (ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company's assets;
- (iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or
- (iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

1) Name of the issuer and its predecessors (if any)

In answering this item, please also provide any names used by predecessor entities and the dates of the name changes.

Current Issuer- Patient Access Solutions Inc. Predecessor-Blue Mountain Resources- name changed October 2008

Date and state (or jurisdiction) of incorporation (also describe any changes to incorporation since inception, if applicable) Please also include the issuer's current standing in its state of incorporation (e.g. active, default, inactive):

2006- Nevada- Active in Good Standing

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

Yes: ☐ No: XX☒

If this issuer or any of its predecessors have been the subject of such proceedings, please provide additional details in the space below:

n/a

2) Security Information

Trading symbol: PASO
Exact title and class of securities outstanding: Common Stock
CUSIP: 70324A208
Par or stated value: .001

Total shares authorized: 750,000,000 as of date: April 2020
Total shares outstanding: 620,668,942 as of date: April 2020
Number of shares in the Public Float¹: 146,425,869 as of date: April 2020
Total number of shareholders of record: 487 as of date: April 2020

All additional class(es) of publicly traded securities (if any):

Trading symbol: PASO
Exact title and class of securities outstanding: Preferred A
CUSIP: 70324A208
Par or stated value: .001
Total shares authorized: 10,000,000 as of date: April 2020
Total shares outstanding: 10,000,000 as of date: April 2020

Transfer Agent

Name: Empire Stock Transfer
Phone: 702-818-5898
Email: info@empirestock.com

Is the Transfer Agent registered under the Exchange Act?² Yes: XX☒ No: ☐

Describe any trading

¹ "Public Float" shall mean the total number of unrestricted shares not held directly or indirectly by an officer, director, any person who is the beneficial owner of more than 10 percent of the total shares outstanding (a "control person"), or any affiliates thereof, or any immediate family members of officers, directors and control persons.

² To be included in the Pink Current Information tier, the transfer agent must be registered under the Exchange Act.

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

3) Issuance History

The goal of this section is to provide disclosure with respect to each event that resulted in any direct changes to the total shares outstanding of any class of the issuer's securities in the past two completed fiscal years and any subsequent interim period.

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares or any other securities or options to acquire such securities issued for services. Using the tabular format below, please describe these events.

A. Changes to the Number of Outstanding Shares SEE ATTACHED

Check this box to indicate there were no changes to the number of outstanding shares within the past two completed fiscal years and any subsequent periods: ☐ D

Number of Shares outstanding as of [Date of] 10/31/19	Opening Balance: Common: 389,752,114 Preferred: 10,000,000 October 31, 2019		-Right-click the rows below and select insert to add rows as needed;						
Beginning of Second Most									
Recent Completed	Opening Balance:								
Year] 10/31/18	Common: 268,205,058 Preferred: 10,000,000 October 31, 2018								
Date of Transaction	Transaction type (e.g. new Issuance, cancellation, shares returned to treasury)	Number of Shares Issued (or cancelled)	Class of Securities	Value of shares Issued (\$/per share) at Issuance	Were the shares Issued at a discount to market price at the time of Issuance? (Yes/No)	individual Entity Shares were Issued to (entitles must have individual with voting / Investment control disclosed).	Reason for share Issuance (e.g. for cash or debt conversion) OR Nature of Services Provided (I f applicable)	Restricted or Unrestricted as of this filing?	Exemption or Registration Type?
-	See attached-	-see attached	-common	-	-	--	-	-restricted	--
--	-----	--	--	--	--	-	--	--	--
--	--	--	-	--	--	-	--	-	--
Shares Outstanding on [Date of this 4/30/2020	Ending Balance: Common: 620,668,942 Preferred: 10,000,000								

Example: A company with a fiscal year end of December 31st in addressing this item for its quarter

ended September 30, 2018, would include any events that resulted in changes to any class of its outstanding shares from the period beginning on January 1, 2016 through September 30, 2018 pursuant to the tabular format above.

Use the space below to provide any additional details, including footnotes to the table above:

Date of Transaction	Type	CERTIFICATE#	HOLDER	NUMBER of SHARES
---------------------	------	--------------	--------	------------------

PASO Stock Issuance

5/8/2018	COMMON		RONALD HARGROVE	250,000
5/8/2018	COMMON		STEVEN MEDINA	1,000,000
5/8/2018	COMMON		RICHARD HEIN	2,000,000
5/8/2018	COMMON		RAYMOND CI-IIN	500 ,000
5/8/2018	COMMON		GREG ALTIER!	500,000
5/8/2018	COMMON		SALVO DAGUANNO	1,00,0 000
5/8/2018	COMMON		HESTIA INVESTMENTS INC	500,000
5/8/2018	COMMON		ROBERT GAYER	150,000
5/8/2018	COMMON		JOHN PAPPAS	75,000
5/9/2018	COMMON		TRINITY FINANCING INVESTMENTS CORP(Trinity Bui)	5,000,000
5/9/2018	COMMON		BORSTE,IN TURKEL PC(Leon Borstein)	500,000
5/ 11 /2018	COMMON		ROBERT GAYER	250,000
5/29/2018	COMMON		EMMANUEL KRAMER	1,250,000
5/29/2018	COMMON		EMMANUEL KRAMER	1,500,000
6/12/2018	COMMON		RAYMOND CHIN	1,00,0 000
6/12/2018	COMMON		GREG ALTIERJ	1,000,000
6/12/2018	COMMON		SALVO DAGUANNO	,1 000,000
6/12/2018	COMMON		THE MINTZ LAW FIRM (Allen Fraade)	100,000
6/12/2018	COMMON		HARRY KAMINSKY	2,000,000
6/12/2018	COMMON		SALVO DAGUANNO	3,000,000
6/14/2018	COMMON		RAYMOND CHIN	2,000,000
6/14/2018	COMMON		SALVO DAGUANNO	2,500,000
6/14/2018	COMMON		GREG ALTIERI	3,000,000
6/14/2018	COMMON		HARRY KAMINSKY	500,000
7/9/2018	COMMON		RIVKA LICITENSTEIN	1,000,000
7/9/2018	COMMON		NOCHUMWOLF	500,000
7/26/2018	COMMON		EMMANUEL ZAVUROV	100,000
7/26/2018	COMMON		EMMANUEL ZAVUROV	500,000
7/26/2018	COMMON		KLEINMAN FAMILY FOUNDATION (Elly Kleinman)	500,000
7/26/2018	COMMON		ZVI JACOBOWITZ	750,000
8/9/2018	COMMON		IRVING SINGER	500,000
8/13/2018	COMMON		MATTHEW DUBLER	75,000
8/15/2018	COMMON		EUGENE INGLES	1,548,210
8/17/2018	COMMON		JEFFERY J. KRUEGER	2,500,000

8/17/2018	COMMON	RANDALL BRODSKY	300 ,000
8/17/20 18	COMMON	RANDALL BRODSKY	200,000
8/17/2018	COMMON	VESTECH SECURITIES, INC.(Brett Williams)	59,978
8/17/2018	COMMON	BRET WILLIAMS	339,878
8/17/2018	COMMON	JAREDBROWN	825,000
8/17/2018	COMMON	MICHAEL BROWN	555,000
8/17/2018	COMMON	AARON BROWN	240 ,000
8/24/2018	COMMON	ELLIOTT POLATOFF	500,000
8/31/2018	COMMON	RONALD GONZALEZ	1,500,000
9/10/2018	COMMON	SOAR HOLDINGS SYNDICATE, LLC (Steven Medina)	500,000
9/26/2018	COMMON	LUIS M. ALMONTE	500,000
9/26/2018	COMMON	TRINITY FINANCING INVESTMENTS CORP (Trinity Bui)	10,500,000
11/6/2018	COMMON	ROSEMARIE ROTUNDO	2,000,000
1/2/2019	COMMON	ZVI JACOBOWITZ	1,500,000
1/8/2019	COMMON	EMMANUEL KRAMER	4,102 ,23 1
2/15/2019	COMMON	VICTOR SCAVO	15 ,000 ,000
3/13/2019	COMMON	RAFIA HAMID	500,000
3/13/2019	COMMON	STEVE MEDINA	1,000,000
3/13/2019	COMMON	RAYMOND CHIN	8,000,000
05 /14/2019	COMMON	SALVO DAGUANNO	5,000,000
06/23/2019	COMMON	MICHAEL KRUEGER	500,000
06/23/2019	COMMON	LAUREN KRUEGER	500,000
08/02/2019	COMMON	MICHAEL KRUEGER	500,000
08/02/2019	COMMON	LAUREN KRUEGER	500,000
08/02/2019	COMMON	JEFFERY KRUEGER	13,250,000
08/05/2019	COMMON	EMMANUEL KRAMER	5,732,825
09/01/2019	COMMON	JAG CAPITAL (Joseph Gonzalez)	23,000,000
09/01/2019	COMMON	ROBERT LINZALONE	10,000,000
09/10/2019	COMMON	HESTIA INVESTMENT (Edward Lee)	2,000,000
09/19/2019	COMMON	JEFFERY KRUEGER	962,000
09/20/2019	COMMON	DREAMTECH INC. (Anthony Pizzolo)	10,000,000
09/20/2019	COMMON	DREAMTECH INC. (Anthony Pizzolo)	3,000,000
09/20/2019	COMMON	DOVECOTE CONSULTING SERVICES (Anthony Pizzolo)	3,000,000
12/10/2019	COMMON	ROBERT LINZALONE	13,000,000
12/10/2019	COMMON	ROBERT LINZALONE	23,000,000
12/10/2019	COMMON	BRUCE WEITZBERG	13,000,000
01/09/2020	COMMON	JEFFERY KRUEGER	7,319,302
01/09/2020	COMMON	RANDALL BRODSKY	576,191
01/15/2020	COMMON	HESTIA INVESTMENTS (Edward Lee)	2,100,000
01/27/2020	COMMON	JOSEPH GONZALEZ	20,000,000
01/27/2020	COMMON	JAG CAPITAL (JOSEPH Gonzalez	23,000,000
01/30/2020	COMMON	136 MICHAEL KRUEGER	5,000,000
01/30/2020	COMMON	137 LAUREN KRUEGER	5,000,000
01/30/2020	COMMON	135 JEFFERY KRUEGER	4,687,412
02/10/2020	COMMON	647 Cortney McCown	2,000,000
02/10/2020	COMMON	648 Joseph Bartnick	500,000 *
02/10/2020	COMMON	535 RONALD GONZALEZ	4,000,000 *
02/10/2020	COMMON	649 Eric Gonzalez	5,000,000 *
02/10/2020	COMMON	650 Patricia Gonzalez	5,000,000 *
02/10/2020	COMMON	631 ELLIOTT POLATOFF	4,500,000 *

02/10/2020	COMMON	651 Matthew Kettermann	1,000,000 *
02/10/2020	COMMON	497 AMJ GLOBAL ENTERTAINMENT LLC(Art Malone)	5,726,954
02/10/2020	COMMON	652 Jeffrey Gullo	1,500,000 *
02/10/2020	COMMON	648 Joseph Bartnick	500,000 *
02/10/2020	COMMON	653 Affinity Advisors, LLC (Dan Luther)	5,000,000 *
02/12/2020	COMMON	654 Lee H. Puglisi	4,000,000 *
03/13/2020	COMMON	135 JEFFERY J. KRUEGER	10,000,000
03/13/2020	COMMON	682 Brian Cesca	250,000
03/13/2020	COMMON	683 Cortney McCown	5,000,000
03/13/2020	COMMON	684 Jarvis Shockey	3,000,000
03/13/2020	COMMON	685 Wong Hang NGA	2,000,000
03/16/2020	COMMON	518 TOPPER PARTNERS I, LLC (Vic Topper)	9,806,969 *
03/17/2020	COMMON	655 Ashley Williams	4,000,000 *
03/17/2020	COMMON	134 JOSEPH GONZALEZ	2,000,000 *
03/18/2020	COMMON	656 Jordan Scott Walker	270,000 *
03/18/2020	COMMON	657 Leslie Iris Kubrick	125,000 *
03/18/2020	COMMON	658 Andrew Howard Kubrick	125,000 *
03/18/2020	COMMON	659 Samantha Danielle Kubrick	10,000 *
03/18/2020	COMMON	660 Alexis Nicole Kubrick	10,000 *
03/18/2020	COMMON	661 Joseph Daniel Secreti	10,000 *
03/18/2020	COMMON	662 Sheldon Walker	5,000,000 *
03/24/2020	COMMON	89 CAROLINE IGLIO	2,000,000
04/01/2020	COMMON	497 JEBAC LLC (Jerry Krystoff)	15,000,000
04/01/2020	COMMON	497 MARK PRESLEY	2,500,000
04/01/2020	COMMON	664 SCOTT IACONO	150,000
04/01/2020	COMMON	665 CARRAN SCHNEIDER	5,000,000
04/07/2020	COMMON	654 LEE PUGLISI	4,000,000
04/07/2020	COMMON	615 FRANK PACKES	2,250,000
04/30/2020	COMMON	136 MICHAEL KRUEGER	10,700,000
04/30/2020	COMMON	137 LAUREN KRUEGER	10,700,000

*The Company approved the issuance of 5,000,000 shares each to Robert linzalone and Bruce Weitzberg for payment of amounts owing on outstanding salaries. Referred to in Financial Statement as Additional Revenue Share payable. Additionally, on November 23, 2017, the Company approved the issuance of a Three year Warrant# 3972 to Robert Linzalone in the amount of 36,000,000 shares and the Company approved the issuance of a three year Warrant# 3973 to Bruce Weitzberg in the amount of 36,000,000 shares. The cost basis for both warrants is .01, and they were issued as an additional offset to salaries due to both executives and listed as Additional Revenue Share payable on the Financial Statements enclosed. The Company approved the issuance of 5,000,000 each to Robert Linzalone and Bruce Weitzberg for payment of amounts owing on outstanding salaries. Referred to in Financial Statement as Additional Revenue Share payable

//

/

B. Debt Securities, Including Promissory and Convertible Notes

Use the chart and additional space below to list and describe any issuance of promissory notes, convertible notes or convertible debentures in the past two completed fiscal years and any subsequent interim period.

Check this box if there are no outstanding promissory, convertible notes or debt arrangements: XX

Date of Note Issuance	Outstanding Balance(\$)	Principal Amount at Issuance (\$)	Interest Accrued (\$)	Maturity Date	Conversion Terms (e.g. pricing mechanism for determining conversion of Instrument to shares)	Name of Noteholder	Reason for Issuance (e.g. Loan, Services, etc.)
--	--	--	--	--	--	--	--

Financial Statements

A. The following financial statements were

prepared in accordance with: **XX**U.S.GAAP
OIFRS

B. The financial statements for this reporting period were prepared by Bruce Weitzberg)
4:

Name: Bruce WeitzBerg
Title: CEO
Relationship to Issuer: Bruce Weitzberg
CEO CEO

Provide the financial statements described below for the most recent fiscal year or quarter. For the initial disclosure statement (qualifying for Pink Current Information for the first time) please provide reports for the two previous fiscal years and any subsequent interim periods.

- C. Balance sheet; ATTACHED
- D. Statement of income; ATTACHED
- E. Statement of cash flows; ATTACHED
- F. Financial notes; and
- G. Audit letter, if audited

You may either (i) attach/append the financial statements to this disclosure statement or (ii) file the financial statements through OTCIQ as a separate report using the appropriate report name for the applicable period end. ("Annual Report, a "Quarterly Report" or "Interim Report").

If you choose to publish the financial statements in a separate report as described above, you must state in the accompanying disclosure statement that such financial statements are incorporated by reference. You may reference the document(s) containing the required financial statements by indicating the document name, period end date, and the date that it was posted to OTCIQ in the field below.

The financial statements requested pursuant to this item must be prepared in accordance with US **GAAP** or IFRS by persons with sufficient financial skills.

OTC Markets Group Inc.
OTC Pink Basic Disclosure Guidelines (v2.1 December 2019)

Page 11 of

15

Patient Access Solutions, Inc.
Statement of Shareholders Equity
For period Ending April 2020

	Preferred Stock @ \$1 par	Common Stock @.001 par	Additional Paid In Capital	Retained Earnings	Treasury Stock	Total
Balance, JANUARY 31,2020	10,000,000	268,205.	144,500	-16,689,043.		-6,276,338
Issuance of additional common stock	0	121,546.				121,546
Purchase of Treasury Stock	0					

Net Income	0					190,027.64
Dividends on Preferred Stock	0	0	0	0		0
Dividends on Common Stock	0	0	0	0	0	0
Balance, APRIL 30,2020	10,000,000	389,752.	156,000	-16,716,428		-6,170,676

- A. Describe any subsidiaries, parents, or affiliated companies, if applicable, and a description of their business contact information for the business, officers, directors, managers or control persons. Subsidiary information may be included by reference

PASHealth management is the subsidiary that oversees and manages the medical facility-Same management

- B. Describe the issuers' principal products
or services, and their markets Healthcare
management

4) Issuer's Facilities

The goal of this section is to provide a potential investor with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer, give the location of the principal plants and other property of the issuer and describe the condition of the properties. If the issuer does not have complete ownership or control of the property (for example, if others also own the property or if there is a mortgage on the property), describe the limitations on the ownership.

If the issuer leases any assets, properties or facilities, clearly describe them as above and the terms of their leases.

150 Veterans hwy, Commack, NY 11725-rented

5) Officers, Directors, and Control Persons

The goal of this section is to provide an investor with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business

development and disclosure of the issuer, as well as the identity of any significant or beneficial shareholders.

Using the tabular format below, please provide information regarding *any* person or entity owning 5% or more of the issuer, as well as *any* officer, and *any* director of the company, regardless of the number of shares they own. If any listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information of an individual representing the corporation or entity in the note section.

Name of Officer/Director and Control Person	Affiliation with Company (e.g. Officer/Director/Owner of more than 5%)	Residential Address (City / State Only)	Number of shares owned	Share type/classes	Ownership Percentage of Class Outstanding	Note
Bruce Weitzberg	CEO	14 fox hollow rd.	3,000,000	common	6.2%	-
		Woodbury, NY				-
Bruce Weitzberg	CEO	14 fox hollow rd.	5,000,000	preferred	50%	-
		Woodbury, NY				-
Robert Linzalone	VP	15 Wheatfield rd	31,000,000	common	6.2%	-
		Commack, NY				-
Robert Linzalone	VP	15 Wheatfield	5,000,000	preferred	50%	-
		Commack, NY				-
Joseph Gonzalez	Director	320 alpha mill rd.	34,500,000	common	6.9%	-
		Charlotte, NC				-

6) Legal/Disciplinary History

A Please identify whether any of the persons listed above have, in the past 10 years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses); None
2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities; None
3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or None
4. The entry of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.
None

no

B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party or of which any of their property is the subject Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities. None

7) Third Party Providers

Please provide the name, address, telephone number and email address of each of the following outside providers:

Securities Counsel

Name: Firm: Legal
Counsel
Labertew and Associates
Po Box 980395
Park city, Utah, 84098
Phone – 801-424-3555
Email –
michael@labertewlaw.com

Accountant or Auditor

Name:	Michael Studer Studer
Firm:	Associates
Address 1:	111 West Sunrise Hwy
Address 2:	Freeport. NY 11520 516-
Phone:	378-1000
Email:	mts@studerpa.com

Other Service Providers

Provide the name of any other service provider(s), including, counsel, advisor(s) or consultant(s) that assisted, advised, prepared or provided information with respect to this disclosure statement, or provided assistance or services to the issuer during the reporting period.

8) Issuer Certification

Principal Executive Officer.

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities).

The certifications shall follow the format

below: I, Bruce Weitzberg certify that:

1. . I have reviewed this April Quarterly report of PASO;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

— [CEO's Signature] 

(Digital Signatures should appear as "/s/ [OFFICER NAME]")

June 15, 2020

Principal Financial Officer.

I, Bruce Weitzberg certify that

1. I have reviewed this April Quarterly report of PASO;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of and for, the periods presented in this disclosure statement.

June 15, 2020 [Date]
[CFO's Signature] 

(Digital Signatures should appear as "/s/ [OFFICER NAME]")

Patient Access Solutions
PROFIT AND LOSS
November 2019 - April 2020

	TOTAL	
	NOV 2019-APR 2020	NOV 2018 - APR 2019 {PY}
Income		
30500 Sales	299,958.00	781,520.98
30560 Sales of Product Income		1,710.01
30570 CIIT Center CM Closed		388.41
Total Income	\$299,958.88	\$183,619.48
GROSS PROFIT	\$299,958.88	\$133,619.48
Expenses		
60000 Advertising	2,624.80	4,312.40
60002 Marketing	300.00	649.00
60100 petty cash	2,422.00	2,920.00
60200 Travel		451.07
60203 Meals and Entertainment		1,573.54
60400 Bank Charges	400.00	1,373.00
60411 Merchant Processing Fees		-41.12
Total 60400 Bank Charges	488.88	1,331.88
61000 Business Licenses and Permits		138.00
61700 Computer/Network Fees	2,840.00	1,420.00
62500 Dues & Subscriptions	680.00	
66704 Filing Fees		50.00
Total 62500 Dues & Subscriptions	688.88	-58.88
63300 Insurance	1,212.46	606.66
63350 Insurance - Disability		986.48
63360 insurance- Malpractice		2,136.97
64400 Other General and Admin Expenses	42,869.23	-28.96
64600 medical supplies	26,592.00	37,869.74
64900 Office Expenses	59,910.20	13,296.95
64904 Telephone		6,658.15
Total 64900 Office Expenses	-59,916.28	19,955.18
64901 Supplies & Materials		1,207.11
64902 Stationery & Printing		21.68
64903 Postage and Delivery		165.00
66001 Payroll Wages-PAS	28,048.00	14,024.00
66003 Wages-Vitality		35,450.00
66700 Legal & Professional Fees	12,998.42	5,050.05
66701 Transfer Agent Fees		1,160.00
66703 Professional Fees		289.36
Total 66700 Legal & Professional Fees	12,998.42	6,499.41
66750 Loan Payable		4,500.00
67100 Rent or Lease	197,925.00	193,369.86
67101 Utilities	11,568.00	21,670.09
69800 Uncategorized Expense		591.53
69811 Consulting expense		25,000.00

TOTAL		
	NOV 2019 - APR 2020	NOV 2018 - APR 2019 {PY}
Payroll Services		92,908.00
Total. Expenses	\$300,300.11	\$469.178.56
NET OPERATING INCOME	\$-98.432.11	\$313.840.84
NET INCOME	\$- 98,432.11	\$313.848.84

Patient Access Solutions

BALANCE SHEET

As of April 30, 2020

	TOTAL	
	AS OF APR 30, 2020	AS OF APR 30, 2019 (PY)
ASSETS		
Current Assets		
Bank Accounts		
7690 Checking TD	14 ,807.74	16 ,251.85
7691 Checking Operating TD	2,686.19	2,686.19
7693 Chase Account	-75.00	-75.00
7694 Bank Transfer	8,787.00	8,787.00
Total Bank Accounts	\$26,205.93	\$27,650.84
Accounts Receivable		
10001 Accounts Receivable (AIR)	2,053,066.77	1,875 ,828 .77
Total Accounts Receivable	"\$2.853.866.77	\$1,875,8211.77
Other Current Assets		
11400 Prepaid Expenses	40 .00	40 .00
12001 Senior Secured Credit cash in escrow pending settlement of NYS income tax withholding liability	12 ,032.00	12 032 . 00
12002 Prepaid rent	23,246.67	23,246.67
12003 Supplies Inventory	7,213.89	7,213.89
13101 Uncategorized Asset	2,984.01	2,984.01
Total Other Current. Assets	16.57	16.57
Total ICurrent.Assets	"\$2.124.789..27	\$1,941,195.38
Fixed Assets		
13000 Furniture & Fixtures	106,337.36	106,337.36
13001 Machinery & Equipment	142,893.19	142,893.19
13002 Computers etal	55,030.46	55,030.46
13005 Leasehold Improvements	383,792.36	383,792.36
13100 Accumulated Depreciation		
131000 Accumulated Depletion- furniture and fixture	-10,426.58	-10,426.58
131001 Accumulated depreciation - machinery and equipment	-11,049.78	-11,049.78
131002 Accumulated Depletion- computers	-6,377.72	-6 377.72
131005 Accumulated Depletion-leasehold improvement	-17,682.84	-17,682.84
Total Accumulated Depreciation	-536..92	-536..92
Total Fixed. Assets	\$642.516.45	\$642.516.45
Other Assets		
11200 Loan to Company	-20,000.00	-20,000.00
14001 Security deposit	46,493.34	46,493.34
Total Other. Assets	\$26,493.34	\$26,493.34
TOIAL.ASSET-S	\$2.793.799.86	\$2.618,,885.17

Patient Access Solutions

BALANCE SHEET

As of April 30, 2020

	TOTAL	
LIABILITIES AND EQUITY	AS OF APR 30, 2020	AS OF APR 30, 2019 (PY)
Liabilities		
Current Liabilities		
Accounts Payable		
20000 Accounts Payable (NP)	240,153.37	128,180.37
Total Accounts Payable	\$240,153.37	\$128,188.37
Other Current Liabilities		
20001 Due to Stella Realty	0.00	0.00
20002 Social security - employer liabilities	-2,307.14	-2,307.14
20003 Social security withhold	-1,107.14	-1,107.14
20004 Federal income tax withhold	-67,666.86	-67,666.86
20005 NYS income tax withhold	-1,029.60	-1,029.60
21001 Loan payable CUT	-195,000.00	-195,000.00
22001 Loan payable - Senior Secured Credit (due 9/15/17)	568,125.00	568,125.00
22002 Debt discounts-loan payable-Senior Secured Credit	-33,118.66	-33,118.66
22003 Interest payable	30,500.00	30,500.00
24110 NYS income tax withholding liability	0.00	0.00
24150 Federal Taxes	158,681.00	158,681.00
25001 Deferred Additional Revenue Share Expense	-500,000.00	-500,000.00
25002 Additional Revenue Share Payable	500,000.00	500,000.00
27001 Series B Preferred Stock (Redeemable and Convertible)	200,000.10	200,000.10
27332 Payroll Liabilities	-11,109.00	-11,109.00
27333 Connect care	3,600.00	3,600.00
45000 Federal Taxes (941/944)	-59,568.92	-59,568.92
45001 Federal Unemployment (940)	799.61	799.61
45002 NY MCTMT Employer Tax	0.00	0.00
45003 NYS Employment Taxes	-12,592.34	-12,592.34
45004 NYS Income Tax	25.90	25.90
Total..27332 Payroll liabilities	-78,844.75	-78,844.75
37 400 Accrued rent expense	0.00	0.00
37401 Convertible Notes	361,000.00	361,000.00
Contra convertible notes payable	-336,000.00	-336,000.00
Due to bruce	500.00	500.00
Total Other Current..l.1aeililies	\$683,395.00	\$683,395.00
Total Current liabilities	\$143,885.32	\$731,912.32
Total liabilities	\$143,885.32	\$731,912.32

Patient Access Solutions

BALANCE SHEET

As of April 30, 2020

	TOTAL	
AS OF APR 30, 2020		AS OF APR 30, 2019 (PY)
Equity		
11301 Common Stock PPM	156,000.00	156,000.00
28001 Common Stock, \$.001 pa	94,695.18	94,695.18
28002 Additional paid-in capital	16,432,684.48	16,432,684.48
28501 Series A Convertible Preferred Stock, \$.001 pa	9,999.90	9,999.90
32000 Retained Earnings	-15,248,334.42	-15,716,428.26
Opening Balance Equity	595,300.71	595,300.71
Net Income	-90,432.11	313,840.84
Total. Equity	\$1,949,913.74	\$1,816,892.85
Total Liabilities and Equity	\$2,793,799.86	\$2,618,885.17

Patient Access Solutions.

STATEMENT OF CASH FLOWS

November 2019 - April 2020

		TOTAL
<hr/>		
OPERATING ACTIVITIES		
Net Income		-90,432.11
Adjustments to reconcile Net Income to Net Cash provided by operations: 10001 Accounts Receivable (NR)		
20000 Accounts Payable (NP)		-22,985.00
Total..Adjustments.Net Income		111,973.00
.Net cash Operating		88.988.00
NET CASH INCREASE FOR PERIOD	\$-1.444.11	
Cash at beginning of period	27,650.04	
CASH AT END OF PERIOD	\$26,285.93-	

Financial statement information is considered current until the due date for the subsequent report (as set forth in the qualifications section above). To remain qualified for Current Information, a company must post its Annual Report within 90 days from its fiscal year-end date and Quarterly Reports within 45 days of each fiscal quarter-end date.

9) Issuer's Business, Products and Services

The purpose of this section is to provide a clear description of the issuer's current operations. In answering this item, please include the following:

C. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")

Patient Access Solutions Inc. has developed and markets the PASHealth Web Portal System. The PASHealth Web Portal System offers electronic medical eligibility, electronic referrals, and service authorizations, electronic claims processing, drug formularies, electronic prescriptions, electronic medical records and patient data, automating the labor intensive and expensive manual process currently used by many facilities and healthcare providers. D-PAS utilizes digital pen & paper, to capture handwritten information for Home Healthcare workers, transfer it into a digital form into the PAS web portal and utilize the data to initiate workflows in a secure environment. A patients' medical history and patient records are used to initiate necessary workflows within the web portal, securely and much more efficiently, empowering the healthcare business process. In addition, the Web Portal System offers a complete suite of self-pay receivable management solutions for the healthcare facilities.

In January 2017 the Company opened up an Integrative Medical Facility in Plainview, New York.

For the second quarter ended April 30, 2020 Recent Developments: As a result of the COVID-19 pandemic, we expected our revenue for the second quarter ended April 30, 2020 to be reduced by 90% compared to our revenue for the second quarter ended April 30, 2019. The rapid spread of COVID-19, as well as the measures governments and private organizations have implemented in order to stem the spread of this pandemic, have had, and are continuing to have, a material adverse effect and consequently upon our business.

- In New York, which is our primary market, the government has encouraged social distancing efforts and limits on gathering size, placed significant restrictions on which kind of medical services are considered "essential";
- State or local governments have issued health-related curfews or "shelter in place" orders which dissuade any provider visits that aren't considered critical/emergency;
- Employers in both the public and private sectors have issued instructions to employees to work from home having a ripple effect on consumers having the ability to visit a physician for elective procedures;
- Consumers discouraged from interacting with society where COVID-19 is particularly virulent;

These effects related to the COVID-19 pandemic are negatively impacting our business in general, which in turn are materially adversely affecting our revenues and results of operations. Although certain of the restrictions above have begun, and may continue, to ease, the ongoing pandemic, including concentrated outbreaks of COVID-19, may result in their reinstitution. Moreover, additional currently unknown restrictions (including possibly in the near term), lengthening the negative effects of the COVID-19 pandemic on our business.

Our operations could be negatively affected further if our employees are sickened as a result of exposure to COVID-19.

In response to the crisis, we are taking certain steps to mitigate the effects on our business, which themselves may have negative consequences with respect to our business and operations. For example, we have significantly reduced our operating capacity. Despite these efforts, we have experienced significant appointment cancellations. Cancellations and related refunds have negatively affected our revenues and liquidity, and we expect such negative effects to continue. Other cost-saving measures that we are implementing or may consider, such as deferral of nonessential maintenance, capital expenditure reductions, hiring freezes. The pandemic is also having a material adverse effect on third parties whose services we utilize. Depending on the duration of the pandemic, such negative developments may occur over the entirety of the event. At this time, we are also not able to predict whether the COVID-19 pandemic will result in permanent changes to our customers' behavior, with such changes including but not limited to a permanent reduction in office visits and treatment. All of the foregoing have had a material adverse effect on our business, results of operations and financial condition.

Patient Access Solutions Inc. ("PASO") was incorporated in the state of Nevada on March 17, 2006. Its wholly owned subsidiary PAS Health Management Companies NY, Inc. ("PASO Health"), incorporated in the state of New York on October 1, 2016, provides

administrative, management, and facility services to health care providers at locations in Plainview New York and Center Moriches New York (see Note 11). PASO also rents equipment to other health care providers.

PASO and PASHealth Management Companies NY are collectively referred to as the "Company".

The Unaudited Financial Statements as of April 30, 2020, have been prepared in accordance with accounting principles generally accepted in the United States. In the opinion of management, the unaudited financial statements reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the financial data and other information disclosed in these notes. The results for these periods are not necessarily indicative of the results to be expected for future periods.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (a) Basis of Presentation and Going Concern

The financial statements are prepared on a "going concern" basis, which contemplates the realization of assets and liabilities in the normal course of business; however, there is substantial doubt as to the Company's ability to continue as a going concern.

The convertible note identified in the Balance Sheet reflects a note for Trinity Financing Investment Group, directors board member agreed and issued 7,299,000 shares to TFIC in order to pay the debt of the loan on August 2017

The Company plans to improve its financial condition by obtaining additional financing and by generating positive cash flow from its future business operations. However, there is no assurance that the Company will be successful in accomplishing its objectives. The financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern.

(b) Principles of Consolidation

The Unaudited Consolidated financial statements include the accounts of PASO and its wholly owned subsidiary PASO Health (collectively, the "Company"). All inter-company balances and transactions have been eliminated in consolidation.

(c) Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.

(d) Cash and Cash Equivalents

The Company considers all liquid investments purchased with original maturities of ninety days or less to be cash equivalents.

(e) Fees and Loans Receivable from Health Care Providers

Fees receivable from health care providers are recorded at net realizable value. The Company periodically assesses the adequacy of valuation allowances for uncollectable receivables by evaluating the collectability of outstanding receivables and general factors such as historical collection experience, length of time individual receivables are past due, and the economic and competitive environment.

(f) Property, Plant and Equipment

Property, plant and equipment is stated at cost less accumulated depreciation and amortization. Depreciation of furniture, fixtures, and equipment is provided using the straight-line method over the estimated useful lives of the respective assets (ranging from five to seven years). Amortization of leasehold improvements is provided over the shorter of the remaining lease term or the assets' useful lives.

(g) Revenue Recognition

Revenue from fees from health care providers and equipment rentals are recognized when all the following criteria are met: (1) persuasive evidence of an arrangement exists